Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Sponsor: Replimune Inc.
Summary
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Official title: A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
280
Start Date
2024-12-17
Completion Date
2031-10
Last Updated
2026-04-02
Healthy Volunteers
No
Conditions
Interventions
RP2
Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
Ipilimumab
Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
Nivolumab
Nivolumab: Anti-PD-1 Monoclonal antibody
Locations (33)
HonorHealth Research Insisute
Scottsdale, Arizona, United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
The Angeles Clinic and Research Institute
Los Angeles, California, United States
University of California Los Angeles
Los Angeles, California, United States
Stanford Cancer Institute
Palo Alto, California, United States
University of Colorado Hospital - Anschutz Cancer Pavilion(ACP)
Aurora, Colorado, United States
The Melanoma & Skin Cancer Institute
Englewood, Colorado, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Mayo Clinic - Jacksonville FL
Jacksonville, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Emory Winship Cancer Institute
Atlanta, Georgia, United States
Northwestern Memorial Hospital
Chicago, Illinois, United States
University of Chicago Medical Center
Chicago, Illinois, United States
University of Iowa
Iowa City, Iowa, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee, United States
University of Tennessee Medical Center
Knoxville, Tennessee, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic)
Nashville, Tennessee, United States
UT Southwestern Medical Center
Dallas, Texas, United States
The University Of Texas Md Anderson Cancer Center
Houston, Texas, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
University Of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, Merseyside, United Kingdom
The Royal Marsden NHS Foundation Trust
London, United Kingdom